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Previewsenvironment or are other master regula-
tors of stress response pathways such
as FoxO3a or p53 (Warr et al., 2011) also
important in tailoring the metabolic
makeup of self-renewing HSCs? Lastly,
aremutations in Pdk2/4 orPtpmt1 associ-
ated with blood diseases and do leu-
kemia-initiating stem cells have changes
in their metabolic wiring that would make
themdistinct fromnormal HSCsandcould
be amenable to therapeutic intervention?
These are just a few of the myriad ques-
tions that are emerging from these two
exciting works, which have brought us
a step closer to understanding HSC stem-
ness from the standpoint of regulation of
energy supply and demand.REFERENCES
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Knowing when to stop proliferation is crucial for any regenerative process. In a recent issue of Nature, Barry
et al. (2012) report that the Hippo pathway component YAP negatively regulates Wnt signaling, thereby
preventing stem cell overpopulation after a regenerative response in the intestine.During homeostasis a complex interplay
of morphogenetic pathways preserve
epithelial integrity in the gut. These path-
ways, which include Wnt and Notch
signaling, maintain a functional stem cell
pool and regulate differentiation pro-
cesses. More recent data indicate that
the same signaling cascades are crucial
for proper tissue regeneration after injury
of the adult intestine. For example, it has
been demonstrated not only that Wnt
signaling is critical for gut repair but also
that artificial increase of Wnt activity,
e.g., by infusion of the Wnt agonist
R-spondin1, augments the efficacy of
the regenerative response (Kim et al.,
2005).
In contrast to our rather extensive
knowledge of pathways that regulatestem cell properties in the intestine during
homeostasis and tissue regeneration,
only a very limited number of studies
examine the mechanisms that keep
stem cells in check after a regenerative
response to prevent tissue overcrowding
and dysplasia. An important player in
this so-called ‘‘crowd control’’ mecha-
nism is the Hippo pathway. This pathway,
originally discovered in Drosophila, is
most well known for its ability to regulate
organ size (reviewed in Mauviel et al.,
2012). When the Hippo cascade is active,
the downstream effector of this pathway
Yes-associated protein (YAP) is phos-
phorylated at S127 by the LATS1/2
kinases. Phosphorylated YAP remains in
the cytoplasm and as such cannot exert
its proproliferative and antiapoptoticfunction in the nucleus, which is mainly
mediated by its binding to TEAD1-4 tran-
scription factors. In addition, cytoplasmic
YAP can directly antagonize the Wnt
pathway, thereby further contributing to
the role of Hippo signaling in preventing
proliferation and stem cell expansion
(Konsavage and Yochum, 2012).
The relevance of the Wnt antagonizing
effects of YAP in controlling intestinal
stem cell expansion after regeneration
was recently uncovered in an elegant
series of experiments performed in the
Camargo laboratory (Barry et al., 2012).
Barry et al. (2012) report that epithelial-
specific overexpression of the YAP
(S127A) mutant, which importantly is pre-
dominantly localized in the cytoplasm in
this tissue, induces intestinal hypotrophyl 12, January 3, 2013 ª2013 Elsevier Inc. 3
Figure 1. A Novel Crosstalk Mechanism between the Hippo andWnt
Pathways
Active Hippo signaling results in phosphorylation of YAP by LATS1/2 kinases.
Phosphorylated YAP remains located in the cytoplasm. Cytosolic-located YAP
interacts directly with Dishevelled (DVL) and inhibits its nuclear translocation.
Nuclear DVL activates, parallel to the canonical Wnt pathway, a Wnt expres-
sion program. YAP is crucial to restrain a Wnt-related regenerative response.
Note that nuclear YAP (orange) functions as an oncogene and induces tran-
scription of a proliferation-inducing and antiapoptotic gene expression
program. Cytosolic YAP (green) functions as a tumor suppressor by inhibiting
the Wnt pathway.
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columnar stem cells. Mecha-
nistically, YAP(S127A) ex-
pression results in abrogation
of Wnt signaling in the intes-
tine in vivo. In agreement
with previous reports, YAP
loss in the intestine only
marginally affects intestinal
homeostasis (Cai et al.,
2010); however, the effects
of YAP loss become signifi-
cant when a Wnt-dependent
regenerative response is
induced either by g-irradia-
tion or by adenovirus-medi-
ated R-spondin1 expression.
In those cases, YAP loss
results in a rapid expansion
of the intestinal stem cell
compartment and forma-
tion of ectopic crypt regions
and even microadenomas,
which is in fact a phenotype
very reminiscent of intestinal
APC loss as observed in
the APCmin mouse model.
These data indicate that
YAP is involved in controlling
the activity of the Wnt path-
way during regeneration and
thereby also preventing tis-
sue hypertrophy and dys-
plasia. The precise mecha-
nism by which this occurs isnot entirely resolved yet, although it is
suggested by Barry et al. (2012) that it
does not involve sequestering of b-cate-
nin in the cytoplasm or inhibition of
GSK3b function within the b-catenin
degradation complex, which are two pre-
viously reported mechanisms by which
cytosolic YAP negatively regulates
Wnt signaling (Konsavage and Yochum,
2012). Instead, Barry et al. (2012) propose
a novel mechanism in which cytoplasmic
YAP directly inhibits nuclear translocation
of Dishevelled proteins where it promotes
Wnt target gene expression, in a parallel
manner to the canonical b-catenin medi-
ated activity of this pathway (Figure 1).
In many respects, cancer can be
perceived as a disease in which stem
cell proliferation is no longer restricted
and causes tissue overpopulation. This
is often a consequence of mutations
causing activation of pathways promoting
stem cell proliferation and self-renewal. A
prime example of this notion is the consti-4 Cell Stem Cell 12, January 3, 2013 ª2013 Etutive activation of the Wnt pathway seen
in the vast majority of colorectal cancers
(CRCs). Consequently, the Wnt target
gene YAP is upregulated in many CRCs.
Interestingly, Barry et al. (2012) now iden-
tify a small fraction of CRCs that show low
expression of YAP protein and that have
a dismal prognosis. The mechanism by
which YAP expression is restricted in
these patients is unclear, but it could
involve promoter methylation that is
also described to be responsible for de-
creased expression of other negative
regulators of the Wnt pathway.
It should be noted that several of
the findings by Barry et al. (2012) con-
trast with previous paradigms of YAP
function that were established in the field.
First of all, the effects of epithelial cell-
specific YAP overexpression in the intes-
tine are opposite to the effects of YAP
overexpression in the skin where it
strongly promotes stem cell expansion
and results in thickening of the skinlsevier Inc.(Schlegelmilch et al., 2011).
There are several possibilities
for this contrasting phenotype
including context-dependent
pathway interactions, differ-
ential roles of the Wnt path-
way in either tissue, or subcel-
lular localization differences
of the YAP(S127A) mutant.
While the biological differ-
ences underlying the discrep-
ancy between the effects of
YAP expression in the skin
and the intestine are not yet
entirely clear, in the gut itself
the effects of YAP overex-
pression are not unambig-
uous either. In the current
study by Barry et al. (2012),
epithelial cell-specific YAP
(S127A) expression results in
a degenerative phenotype;
however, when the same YAP
mutant is expressed using
a ubiquitous promoter, intes-
tinal dysplasia with expansion
of undifferentiated progenitor
cells is observed (Camargo
et al., 2007). These results
are especially intriguing as it
indicates that the Hippo path-
way mediates potent para-
crine effects of the intestinal
stroma, a concept that is in
linewith a recent study report-ing that YAP expression indeed has para-
crine functions and promotes secretion of
the EGFR ligand amphiregulin (Zhang
et al., 2009).
To conclude, the current work suggests
that YAP is a tumor suppressor gene in
CRC, as Barry et al. (2012) additionally
showed that patients with low YAP
expression levels have a poor prognosis
and overexpression of YAP results in
impaired subcutaneous tumor growth of
the DLD-1 CRC cell line. Intriguingly,
these findings appear to be counterintui-
tive based on previous work. Two recent
reports showed that shRNA-mediated
downregulation of YAP in a panel of
CRC cell lines inhibits colony formation
and subcutaneous tumor growth (Kon-
savage et al., 2012; Zhou et al., 2011),
which would be inconsistent with a tumor
suppressor role for YAP in the intestine.
One possibility for resolving these oppos-
ing findings can be reached by appre-
ciating the different functions YAP has
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Previewsdepending on its subcellular localization.
In this respect, nuclear YAP is thought to
function mainly as an oncogene and
promotes proliferation and expression of
antiapoptotic proteins, while cytoplasmic
YAP is a typical tumor suppressor that
downregulates the Wnt pathway. If this
hypothesis is true, it will be a true chal-
lenge to appropriately target thismolecule
for clinical benefit. Clever strategies need
to be developed that selectively inhibit the
oncogenic properties of this protein while
promoting the tumor suppressor func-
tions. Potentially, this could be achieved
by interfering with the YAP-TEAD interac-
tion or by inhibiting its nuclear transloca-
tion. In any case, it will be interesting to
follow how efforts to manipulate YAP
function will develop.REFERENCES
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